5 unknown, 1 completed. 4 Phase 2, 3 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Unknown 3, Completed 1 |
| Phase 1 | 3 | Unknown 3 |
| Phase 4 | 1 | Unknown 1 |
Follow ALK-Positive Anaplastic Large Cell Lymphoma: new trials by email Literature Review of ALK-Positive Anaplastic Large Cell Lymphoma trials Research Report on ALK-Positive Anaplastic Large Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Deciphering the Role of Circular RNAs in ALKpositive Anaplastic Large-cell Lymphoma RNAseq - ALK-Positive Anaplastic Large Cell Lymphoma | Unknown | University Hospital, Toulouse | 80 | 2023-01-01 | 2023-07-06 | |
| Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL PD-1 Antibody, Lenalidomide - Non-GCB/ABC Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Huiqiang Huang | 30 | 2021-03-31 | 2021-03-15 |
| Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL Camrelizumab, Apatinib - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Huiqiang Huang | 33 | 2020-07-23 | 2021-03-15 |
| Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma Toripalimab, Rituximab, R-CHOP Protocol - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Huiqiang Huang | 140 | 2020-04-24 | 2022-04-14 |
| Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL Crizotinib, Etoposide Capsule, Auto-HSCT - ALK-Positive Anaplastic Large Cell Lymphoma | Phase 4 | Unknown | Mingzhi Zhang | 20 | 2018-10-01 | 2018-10-16 |
| Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms Tislelizumab - Peripheral T Cell Lymphoma, PTCL | Phase 2 | Completed | BeiGene | 77 | 2018-04-13 | 2024-10-26 |
Pyloric Stenosis, Hypertrophic (3) · Recurrence (3) · Lymphoma, Large B-Cell, Diffuse (2) · Immunoblastic Lymphadenopathy (1) · Lymphoma, Extranodal NK-T-Cell (1) · Lymphoma, Large-Cell, Anaplastic (1) · Lymphoma, T-Cell (1) · Lymphoma, T-Cell, Cutaneous (1) · Lymphoma, T-Cell, Peripheral (1) · Neoplasms (1)
Digestive System Diseases (3) · Disease Attributes (3) · Gastric Outlet Obstruction (3) · Gastrointestinal Diseases (3) · Hemic and Lymphatic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphatic Diseases (3) · Lymphoma (3) · Lymphoma, Non-Hodgkin (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3)
tislelizumab (2) · Base Sequence (1) · Crizotinib (1) · Etoposide (1) · Lenalidomide (1) · R-CHOP protocol (1) · Rituximab (1) · apatinib (1) · camrelizumab (1) · spartalizumab (1) · toripalimab (1)
Huiqiang Huang (3) · BeiGene (1) · Mingzhi Zhang (1) · University Hospital, Toulouse (1)
China (5) · France (2) · Canada (1) · Italy (1) · Taiwan (1)
Huiqiang Huang, Professor (1) · Laurence Lamant (1)
2017 (1)